Advertisement


R. Katie Kelley, MD, on Biliary Tract Cancer: Data From KEYNOTE-966 on Pembrolizumab, Gemcitabine, and Cisplatin

AACR Annual Meeting 2023

Advertisement

R. Katie Kelley, MD, of the Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco, discusses phase III findings of the KEYNOTE-966 study, which showed that adding the immune checkpoint inhibitor pembrolizumab to gemcitabine and cisplatin improved overall survival in patients with untreated metastatic or unresectable biliary tract cancer. (Abstract CT008)



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
The KEYNOTE-966 study was a randomized international phase three placebo controlled trial in advanced biliary tract cancers. Now, advanced biliary tract cancers are a complex family of epithelial cancers arising from the biliary tree in the gallbladder, and they include intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma and gallbladder cancers. These are very difficult cancers to treat with poor prognosis overall, and they're actually rising in incidents worldwide, making biliary tract cancers an area of significant unmet need. The standard treatment for biliary tract cancers for over a decade has been the combination of gemcitabine plus cisplatin chemotherapy, but with this regimen the median survival has been less than a year, and we've been in great need of new therapies. Immunotherapy with immune checkpoint inhibitors has not been very successful by itself with usually around 10% of patients or less showing a response. In the KEYNOTE-966 study, we examined the combination of standard key chemotherapy with the gemcitabine post cisplatin regimen, along with an immune checkpoint inhibitor targeting PD-1 called pembrolizumab. And the rationale for this combination is that both gemcitabine and cisplatin can alter the immune microenvironment and increase the chances of a tumor provoking or prompting an immune response, thereby increasing the chances of eliciting an immune response with the addition of immune checkpoint inhibitor. So with the KEYNOTE-966 study, the design included patients with advanced or unresectable or metastatic intrahepatic or extrahepatic cholangiocarcinoma or gallbladder cancer who had not had any prior systemic therapy, so patients were systemic therapy naive, and patients had to have measurable disease and adequate organ status and performance status. Patients were randomized one-to-one to either the combination with pembrolizumab plus gemcitabine and cisplatin or placebo with the same chemotherapy. And the primary endpoint of the study was overall survival with key secondary endpoints including progression-free survival and objective response rate and duration of response. Patients were stratified according to region of the world disease stage and the site of tumor within the biliary tree, either intrahepatic, extrahepatic or gallbladder location. In KEYNOTE-966, a total of 1069 patients were randomized making the study the largest randomized trial in biliary tract cancers to date to our knowledge. Of those patients randomized, around 45% of patients were enrolled from Asian sites and around 55% of patients were enrolled from non-Asian or Western sites, making it a very broadly representative global population. Around 60% of patients had tumors arising from the intrahepatic bile duct, called intrahepatic cholangiocarcinoma, as their site of tumor and around 90% of patients had metastatic disease. Patients were well-balanced between the two treatment arms. So on the treatment, the primary endpoint of overall survival showed a median overall survival with the pembrolizumab plus chemotherapy combination of 12.7 months, compared to 10.9 months for placebo. With a hazard ratio of 0.83 and a P value of 0.0034, which met the criteria for statistical significance and indicated that this was a positive study. And not just meeting statistical significance, we also saw clinically meaningful significance of these results with a clear separation of the survival curve starting around three months into treatment that was sustained throughout the course of the study and also clinically relevant improvements in the proportion with survival at time points of 12 and 24 months. Survival benefit was relatively similar across key pre-specified subgroups including age and region of the world, Western versus non-Western, Asian versus non-Asian, as well as according to PD-L1 tumor expression status. The benefit seemed greatest in the subgroup with intrahepatic cholangiocarcinomas compared to extrahepatic or gallbladder, though again these were just descriptive subgroup analyses. Progression-free survival showed a trend towards improvement in the median with median progression-free survival for the pembrolizumab plus chemo arm of 6.5 months compared to 5.6 months for placebo. This did not meet statistical significance but trended in similar to the overall survival primary endpoint. And lastly, objective response rate was the same in both arms at 29%, but the responses were much longer in the pembrolizumab arm with median of 9.7 months for pembrolizumab plus chemo versus 6.9 months for placebo plus chemo. The safety was quite similar between the two arms overall without any unexpected safety signals. Treatment related adverse events of grade three or four in severity occurred in 70% of the pembrolizumab plus chemo arm versus 69% for the placebo plus chemo arm. So again, quite similar and discontinuation rates were identical for all study drugs between the two arms. Immune-related toxicities requiring steroids occurred in about 9% of the pembrolizumab arm compared to 5% of the placebo arm. Again, very much in line with what we expect for pembrolizumab as monotherapy and showing no signs of any increased rate of immune-related toxicity with the combination. So in sum, putting these data together, we found that the combination of pembrolizumab with gemcitabine and cisplatin standard chemotherapy provided a statistically significant improvement in overall survival, which was meaningful with the longer proportion of patients surviving at time points as far out as 24 months. The duration of responses was longer in the combination arm containing pembrolizumab, suggesting potential for prolonged responses with this immunotherapy addition. And the adverse event profile was as expected for all of the known drugs without significant increase from the combination arm. So collectively, we found that the status supports the addition of pembrolizumab to standard gemcitabine and cisplatin as a potentially new treatment option for patients with untreated metastatic or unresectable biliary tract cancer.

Related Videos

Issues in Oncology

Carmen E. Guerra, MD, MSCE, on Strategies for Equitable Access to Cancer Clinical Trials

Carmen E. Guerra, MD, MSCE, of the University of Pennsylvania Abramson Cancer Center, discusses the ways in which community outreach, programs to help patients access cancer clinical trials, and institutional policies such as ASCO’s Just Ask program can help increase equity, diversity, and inclusion in cancer clinical trials and reduce unconscious bias.

Lung Cancer

John V. Heymach, MD, PhD, on NSCLC: New Data on Durvalumab Plus Chemotherapy From the AEGEAN Trial

John V. Heymach, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses phase III results from the AEGEAN trial, which showed that patients with treatment-naive, resectable, non–small cell lung cancer (NSCLC) who received neoadjuvant durvalumab plus chemotherapy and adjuvant durvalumab monotherapy had improved event-free survival and pathologic complete response, compared with those who received neoadjuvant chemotherapy alone. (Abstract CT005)

Skin Cancer

Jeffrey S. Weber, MD, PhD, on Melanoma: New Data on a Cancer Vaccine Combined With Pembrolizumab

Jeffrey S. Weber, MD, PhD, of the Perlmutter Cancer Center at New York University Langone, discusses efficacy and safety results from the phase II KEYNOTE-942 trial, which showed that a personalized mRNA-based cancer vaccine, combined with the immune checkpoint inhibitor pembrolizumab, improved recurrence-free survival compared with pembrolizumab alone in patients with high-risk melanoma. The clinical benefit was observed regardless of the tumor mutational burden status. (Abstract CT001)

Issues in Oncology

Harry Klein, PhD, on MatchMiner: An Open-Source AI Precision Medicine Trial Matching Platform

Harry Klein, PhD, of Dana-Farber Cancer Institute, discusses MatchMiner, a software platform launched in 2017, that matches patients with appropriate clinical trials of targeted therapies. The platform uses data on the genetic features of a patient’s cancer, as well as clinical data, to identify trials at Dana-Farber for which the patient might be eligible. MatchMiner can also help recruit patients who meet the trial’s eligibility requirements. (Abstract 1067)

Solid Tumors

Timothy A. Yap, MD, PhD, on New Findings on Treating Solid Tumors With PARP and ATR Inhibitors

Timothy A. Yap, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses safety and efficacy data on three different PARP inhibitors combined with the ATR inhibitor camonsertib in patients with solid tumors harboring DNA damage response alterations. The findings showed that low-dose intermittent regimens of camonsertib and different PARP inhibitor combinations were safe. In addition, anticancer activity was observed in patients with platinum- and PARP inhibitor–resistant tumors. Patients with late-line ovarian cancer derived the most benefit from therapy. (Abstract CT018)

Advertisement

Advertisement




Advertisement